Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4
- PMID: 24348648
- PMCID: PMC3860073
- DOI: 10.5812/hepatmon.13678
Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4
Abstract
Background: Three single nucleotide polymorphisms (SNPs) near interleukin-28B (IL-28B) gene were shown to be highly associated with treatment response (SVR) in patients with chronic hepatitis C virus (HCV) infection. There is limited data about the role of single and combined IL-28B polymorphisms in HCV-infected Polish population.
Objectives: This study's aim was to determine predictability of three IL-28B gene polymorphisms and other known prognostic factors on the treatment response in HCV genotype 1 and 4 infected Polish patients. The effect of IL-28B polymorphisms on therapy was also compared with other known prognostic factors.
Patients and methods: We genotyped IL-28B polymorphisms (rs12979860, rs12980275 and rs8099917) by polymerase chain reaction-based restriction fragment length polymorphism assay in a group of 293 patients from which a selected cohort of 174 treatment-naiev patients underwent treatment.
Results: We showed that rs12979860 CC [odds ratio (OR) = 4.6, P < 0.001], rs12980275 AA (OR = 2.9, P = 0.002) and rs8099917 TT (OR = 2.2, P = 0.016) genotypes were associated with successful treatment compared to the rs12979860 CT-TT, rs12980275 AG-GG and rs8099917 TG-GG, respectively. Patients bearing of IL-28B profile including the three favourable genotypes do not have much chance of a recovery (OR = 3.4, P = 0.002). Except for IL-28B polymorphisms, there was no association of SVR with any other pretreatment clinical data in analyzed group. The correlation of SNPs with other host and viral factors revealed association of favorable genotypes of IL-28B markers with high levels of alanine aminotransferase and baseline HCV viral load.
Conclusions: IL-28B polymorphisms were the strongest pretreatment predictors of response to pegylated interferon and ribavirin in Polish patients chronically infected with HCV genotype 1 and 4. This study confirm the strongest impact of IL-28B rs12979860 on SVR, nevertheless rs12980275 AA seems to be more important than rs8099917 TT in predicting positive treatment response.
Keywords: Hepatitits C; Human; IL28B Protein; Interferon-alpha; Polymorphism; Single Nucleotide.
Figures


Similar articles
-
Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.Eur J Clin Microbiol Infect Dis. 2013 Jun;32(6):745-54. doi: 10.1007/s10096-012-1799-z. Epub 2013 Jan 13. Eur J Clin Microbiol Infect Dis. 2013. PMID: 23314745 Free PMC article.
-
Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients.J Viral Hepat. 2012 Sep;19(9):650-3. doi: 10.1111/j.1365-2893.2012.01606.x. Epub 2012 Apr 1. J Viral Hepat. 2012. PMID: 22863269
-
The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients.Virology. 2013 Sep;444(1-2):292-300. doi: 10.1016/j.virol.2013.06.025. Epub 2013 Jul 16. Virology. 2013. PMID: 23866096
-
Association of Interleukin 28B Polymorphism with Clearance of Hepatitis C Virus: A Mini Review.Crit Rev Eukaryot Gene Expr. 2020;30(3):223-229. doi: 10.1615/CritRevEukaryotGeneExpr.2020029692. Crit Rev Eukaryot Gene Expr. 2020. PMID: 32749108 Review.
-
Innate immunity: a new chapter for hepatitis C.Ann Gastroenterol. 2012;25(3):232-240. Ann Gastroenterol. 2012. PMID: 24714071 Free PMC article. Review.
Cited by
-
The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C.PLoS One. 2015 Jun 26;10(6):e0130899. doi: 10.1371/journal.pone.0130899. eCollection 2015. PLoS One. 2015. PMID: 26115415 Free PMC article.
-
The influence of anti-HBc status on the sustained virological response rate in HCV-infected patients treated with pegylated interferon alfa 2 and ribavirin.Clin Exp Hepatol. 2016 Dec;2(4):155-160. doi: 10.5114/ceh.2016.63873. Epub 2016 Nov 28. Clin Exp Hepatol. 2016. PMID: 28856281 Free PMC article.
-
Genetic screening to avoid adverse drug reactions from medication use and approach patients' better outcomes: A lesson learn from the report of the Queen Savang Vadhana Memorial Hospital.Health Sci Rep. 2022 Apr 13;5(3):e591. doi: 10.1002/hsr2.591. eCollection 2022 May. Health Sci Rep. 2022. PMID: 35509409 Free PMC article.
-
Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.World J Gastroenterol. 2015 Aug 7;21(29):8935-42. doi: 10.3748/wjg.v21.i29.8935. World J Gastroenterol. 2015. PMID: 26269684 Free PMC article.
-
Genetic predictors of the response to the treatment of hepatitis C virus infection.Bosn J Basic Med Sci. 2015 Nov 12;15(4):55-9. doi: 10.17305/bjbms.2015.632. Bosn J Basic Med Sci. 2015. PMID: 26614853 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous